IRDAI probes Care Health's stock option issue to Saluja

IRDAI revealed that a probe into stock option allotment to Saluja is on in response to a query raised by Rahul Kanoj under the Right to Information Act (RTI) to the insurance regulator. The regulator said in its response, "The information sought is not furnished as the same would impede the process of investigation or apprehension." ET has seen IRDAI's response to the RTI query.

Mumbai: The and of India () is investigating the issuance of in Insurance to , the firm's non-executive chairperson.

Saluja is the executive chairperson of (REL), which owns Care Health.

IRDAI revealed that a probe into stock option allotment to Saluja is on in response to a query raised by Rahul Kanoj under the Right to Information Act (RTI) to the insurance regulator. The regulator said in its response, "The information sought is not furnished as the same would impede the process of investigation or apprehension." ET has seen IRDAI's response to the RTI query.

Care Health had allotted stock options worth ₹250 crore to Saluja, representing approximately 2.5% of the unlisted insurer's shareholding. InGovern said stock options were issued with an exercise price of ₹45.32 per share in January 2022, while in the same year, a rights issue of CARE shares was priced at ₹110 per share.

Kanoj had filed an RTI query dated April 9, 2024, with IRDAI. In its response, the regulator said Care had sought its approval to grant to Saluja on December 31, 2021. IRDAI said it had rejected this request from Care. Yet, the health insurance company allotted the stock options to Saluja.

Email queries to IRDAI and spokesperson went unanswered till Wednesday press time.

InGovern said Religare did not seek shareholder approval for the allotment of Care shares to Saluja, and there was no disclosure of this matter.

Earlier, the Burman family, which is the largest shareholder of Religare Enterprises, alleged that 22.7 million options in Care have been illegally issued to Saluja.

Burmans, promoters of , and Religare's board led by Saluja are locked in a dispute with both sides accusing each other of violating rules on corporate governance and insider trading.

On October 18, independent directors of Religare wrote a letter to regulators, including the Reserve Bank of India, Sebi, and the insurance watchdog, levelling allegations of fraud and other breaches against the Burmans.


Source: Stocks-Markets-Economic Times

Последние публикации
Ukraine's attacks on Russian territory may 'warrant' nuclear response under Putin's proposed nuclear doctrine changes
25.09.2024 - 22:00
Costco, Accenture, Vail Resorts, and more to report earnings Thursday
25.09.2024 - 22:00
Industry veteran: Forget the Fed, focus on semiconductors and infrastructure
25.09.2024 - 22:00
US urges freight railroads to guarantee paid sick leave for all
25.09.2024 - 22:00
GDP, jobless claims, and Powell speech highlight Thursday's economic data
25.09.2024 - 22:00
Meta climbs after unveiling new AR glasses, AI updates
25.09.2024 - 22:00
Meta shows off prototype augmented-reality glasses at Connect event
25.09.2024 - 22:00
Ford, GM shares fall after Morgan Stanley analyst downgrade
25.09.2024 - 21:00
Shares of Trump's media company rebound from all-time low
25.09.2024 - 21:00
MercadoLibre's fintech arm applies for banking license in Mexico
25.09.2024 - 21:00
US stocks take breather, but remain close to record levels
25.09.2024 - 21:00
Meta shows off new Quest 3S headset to kick off Connect event
25.09.2024 - 21:00
Earnings call: Worthington Enterprises announces mixed Q1 results
25.09.2024 - 20:00
Volkswagen digs in as workers threaten strikes over plant closures
25.09.2024 - 20:00
FTC announces crackdown on deceptive AI claims, schemes
25.09.2024 - 20:00

© Analytic DC. All Rights Reserved.

new
Обзор рынка ЗАПАСЫ СЫРОЙ НЕФТИ В США -4,471М
Добро пожаловать в чат поддержки!
*
*

Ваш запрос успешно отправлен!
Скоро с вами свяжутся.